Immatics N.V. Ordinary Shares - IMTX STOCK NEWS

Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company focused on T cell-redirecting cancer immunotherapies, has announced the pricing of its public offering. The company is offering 16,250,000 ordinary shares at a public offering price of $9.25 per share. The gross proceeds from the offering are expected to be approximately $150 million, before deducting underwriting discounts and offering expenses.

The offering is set to close on October 15, 2024, subject to customary closing conditions. Immatics has also granted the underwriters a 30-day option to purchase up to 2,437,500 additional shares at the public offering price, less the underwriting discount. Jefferies, BofA Securities, and Leerink Partners are acting as joint book-running managers for the offering.

Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company focused on T cell-redirecting cancer immunotherapies, has announced the commencement of an underwritten public offering of its ordinary shares. The offering, subject to market conditions, has no guaranteed completion or defined terms. Jefferies, BofA Securities, and Leerink Partners are acting as joint book-running managers. A registration statement has been filed with the SEC and became effective on October 10, 2024. The offering will be made through a prospectus supplement and accompanying prospectus, available on the SEC's website. This announcement does not constitute an offer to sell or a solicitation of an offer to buy these securities.

Immatics announced updated Phase 1b clinical data on ACTengine® IMA203 TCR-T targeting PRAME in 28 heavily pretreated metastatic melanoma patients. Key findings include:

- Confirmed objective response rate of 54% with median duration of response of 12.1 months
- Median progression-free survival (PFS) of 6 months
- Favorable tolerability profile maintained
- Patients with deep responses show median PFS of more than one year

Based on these results, Immatics will proceed to a registration-enabling Phase 3 trial called 'SUPRAME'. This trial will enroll 360 patients with unresectable or metastatic melanoma post-treatment with a checkpoint inhibitor. The primary endpoint for full approval will be median PFS. The trial is set to commence in December 2024, with enrollment forecasted to complete in 2026.

Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company focused on T cell-redirecting cancer immunotherapies, has announced upcoming presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer in Houston, Texas from November 6-10, 2024. The company will deliver two oral presentations and five poster presentations.

The oral presentations will cover:

• ACTengine IMA203 TCR-T targeting PRAME, showing deep and durable anti-tumor activity in heavily pretreated solid cancer patients
• Enhanced pharmacology data of next-generation IMA203CD8 TCR-T monotherapy targeting PRAME

The poster presentations will address various topics including T cell persistence monitoring, allogeneic γδ T cell production, PRAME-targeting therapies, and TCR-engineered T cells with enhanced persistence.

Immatics presented clinical proof-of-concept data for its TCER® IMA401 targeting MAGEA4/8 at ESMO 2024. The Phase 1 dose escalation trial showed initial anti-tumor activity and a manageable tolerability profile in heavily pre-treated patients with various solid tumors. Key findings include:

- Objective response rate (ORR) of 29% and disease control rate (DCR) of 53% in the efficacy population
- Durable responses lasting up to 13+ months
- Median terminal half-life of over two weeks, supporting q2w dosing
- Manageable safety profile with transient lymphopenia and mild to moderate CRS as most frequent treatment-related AEs

Immatics will regain full rights to IMA401 as Bristol Myers Squibb ends collaboration due to portfolio prioritization. The company plans to advance IMA401 further, with the next data update expected in 2025.

Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company focused on T cell-redirecting cancer immunotherapies, has announced an upcoming oral presentation at the 21st International Congress of the Society for Melanoma Research. The presentation will feature updated clinical data on the company's lead cell therapy candidate, ACTengine® IMA203, which targets PRAME in PD1-refractory metastatic melanoma.

The presentation is scheduled for October 11, 2024, from 8:00 to 8:20 am CDT, during the Plenary Session 1 on Developmental Immunotherapy. Dr. Martin Wermke from the University Hospital Dresden, Germany, will deliver the presentation titled 'ACTengine IMA203 TCR-T targeting PRAME in PD1-refractory metastatic melanoma – Clinical Update'.

Immatics N.V. (NASDAQ: IMTX) reported its Q2 2024 financial results and provided a business update. Key highlights include:

- ACTengine® IMA203 targeting PRAME showed a 55% confirmed objective response rate in 30 metastatic melanoma patients, with a median duration of response of 13.5 months.

- First Phase 1 data from TCER® IMA401 (MAGEA4/8) to be presented at ESMO Congress 2024.

- Cash position of $568.5 million as of June 30, 2024, funding operations into 2027.

- Q2 2024 revenue was $20.1 million, with a net loss of $19.3 million.

- Appointment of Alise Reicin M.D. to Board of Directors.

Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company focused on T cell-redirecting cancer immunotherapies, has appointed Alise Reicin, M.D., to its Board of Directors. Dr. Reicin, currently President and CEO of Tectonic Therapeutic, brings extensive experience in clinical development, including her role in the approval of Keytruda®. Her appointment comes as Immatics advances its pipeline of TCR-based cell therapy and bispecific product candidates.

Peter Chambré, Chairman of Immatics' Board, highlighted Dr. Reicin's expertise in facilitating the approval and launch of novel therapies. Dr. Reicin expressed enthusiasm for Immatics' potential, particularly noting the deep and durable responses from its lead cell therapy candidate, ACTengine® IMA203, in advanced metastatic melanoma patients. Her appointment continues through the Company's Annual General Meeting in 2025.

Immatics N.V. (NASDAQ: IMTX) has announced an upcoming oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024. The presentation will showcase the first proof-of-concept clinical data for TCER® IMA401, their next-generation, half-life extended TCR Bispecific molecule targeting MAGEA4/8.

The presentation, titled "Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR Bispecific, in Phase 1 dose escalation," will be delivered by Dr. Martin Wermke from University Hospital Dresden, Germany. It is scheduled for September 16, 2024, at 11:25 CEST in the Granada Auditorium - Hall 6, as part of the Investigational Immunotherapy session.

Full abstracts will be available on the ESMO website on September 9, 2024, at 00:05 CEST.